Dennen, S., Masek, M., Cockrum, P., Paluri, R. K. (2025). Real-world excess costs associated with hematologic adverse events (hAEs) during first-line (1L) treatment of metastatic pancreatic adenocarcinoma (mPDAC) with FOLFIRINOX (FFX), FFX without 5FU bolus, and gemcitabine+nab-paclitaxel (GnP).. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2025.43.4_suppl.693